Apotea, Sweden’s largest online pharmacy, is set to make its debut on the stock market under the symbol APOTEA. The offering includes 28.18 million existing shares, representing 27.4% of the company’s shares, being sold by current shareholders Laulima, Alecta Tjänstepension, SEB Life International Assurance Company, Neudi Kapital, and Creades.
The stock price has been set at 58 Swedish kronor per share, valuing the total shares at 6.036 billion kronor. Apotea will not be raising any capital through this offering and will not receive any liquidity from it. There is also an over-allotment option to sell an additional 4.22 million shares at the same price, making up 15% of the offering. If this option is fully exercised, the offering will consist of up to 32.41 million shares, representing 31.1% of the company’s shares.
The total value of the offering, if fully subscribed, amounts to 1.635 billion kronor, or 1.88 billion kronor if the over-allotment option is utilized in full. Anchor investors, including funds managed by Capital Group, Nordea Asset Management, WCM Investment Management, Ramsbury Invest, and AMF Aktiefond Småbolag, have committed to acquiring shares in the offering for a total of 975 million kronor.
Public subscription in Sweden will be open from November 27 to December 4, while institutional investors can subscribe from November 27 to December 5. Key stakeholders, including Pär Svärdson, Laulima, other board members and executives, and existing shareholders, have agreed to lock-up commitments for specified periods ranging from 90 to 1,080 days.
Pär Svärdson, CEO, board member, and co-founder of Apotea and Laulima, expressed his excitement about the upcoming listing on Nasdaq Stockholm, highlighting Apotea’s profitable growth journey and its leading position in the Swedish online pharmacy market. He emphasized the company’s commitment to innovation and customer-centric approach, inviting new shareholders to join them in shaping the next chapter of Apotea’s success story.
The planned IPO of Apotea signifies a significant milestone in the company’s trajectory, marking a strategic move to expand its presence and strengthen its market position. With a solid track record of growth and a clear vision for the future, Apotea is poised to redefine the landscape of pharmacy services and deliver value to its shareholders and customers alike.